Takeda Pharmaceutical Company Limited announced today it will establish four new commercialsubsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium andLuxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, S.A. deC.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda PharmaceuticalsNordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) – arepart of Takeda’s strategic global expansion efforts. “Takeda has a significant opportunity to expand our presence in Mexico,Europe and other priority markets,” said Alan MacKenzie, Executive VicePresident (EVP) International Operations, Takeda PharmaceuticalsInternational, Inc. “Executing our territory expansion strategy is animportant step toward further globalizing our operations and enhancing ourability to bring important medicines to patients who need them.” The Mexican pharmaceutical market is the 12th largest in the world andaccounts for approximately 25 percent of the pharmaceutical sales throughoutLatin America. The population in Mexico is increasing, and access tohealthcare continues to grow, with the market increasing faster than in theUnited States and Europe, making it a key region for Takeda’s expansion.Nordics and Benelux are strategically important regions in Europe -Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceuticalmarket size which accounts for five percent of the European pharmaceuticalmarket. Following the buy-back of Actos@ (pioglitazone) in October 2008,Takeda will be distributing Actos in the five countries. The creation of thesecommercial subsidiaries will further increase Takeda’s reach in the regions. The Turkish pharmaceutical market is one of the largest globalpharmaceutical markets, ranked sixth in Europe and 13th worldwide with thefastest forecasted growth rate in Europe over the next five years. Takeda alsorecently re-acquired the rights to Actos in this market, providing thebusiness with a strong product with which to enter the market. Overall, the new subsidiaries will accelerate Takeda’s expansion effortsfor core products including Actos and reinforces Takeda’s global operatinginfrastructure. The company will work toward the earliest possible approvaland launch of new products in these regions. Takeda’s presence in these sevennew countries builds upon other expansions announced in 2009 includingcommercial operations in Spain, Portugal, Ireland, and Canada.